Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders - Wikidata - wikimedia - TriplyDB

Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders

Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders

http://www.wikidata.org/entity/Q30372351

about

nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.Frontal lobe alterations in schizophrenia: a review.Multitarget drug design strategy in Alzheimer's disease: focus on cholinergic transmission and amyloid-β aggregation.Understanding the Bases of Function and Modulation of α7 Nicotinic Receptors: Implications for Drug Discovery.The development of novel polypharmacological agents targeting the multiple binding sites of nicotinic acetylcholine receptors.Insights into nicotinic receptor signaling in nicotine addiction: Implications for prevention and treatment.Molecular Imaging of the Nicotinic Cholinergic Receptor in Alzheimer Disease.

P2860

Q30362464-04E5FF50-97F5-4D55-9153-6FD65B95A8F0 Q36246546-049910A0-0D58-4780-B7E1-B806CE911E97 Q38668998-EC8F224F-F66E-4199-A409-CD92AC40F16B Q38837028-9122D033-A253-4FC0-A6B8-1BCB90EBFFA1 Q38934855-31F02243-C8D8-4251-9FE2-823D58DB69AA Q40111690-FB88CD6F-262D-4F1A-B7A9-E6B863E4E74F Q42379925-F73D639F-F668-4DCF-9F54-DA8F5DFBA710

P2860

Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders

http://www.wikidata.org/entity/Q30372351

description

2015 nî lūn-bûn

@nan

2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Nicotinic ligands as multifunc ...... of neuropsychiatric disorders

@ast

Nicotinic ligands as multifunc ...... of neuropsychiatric disorders

@en

type

label

Nicotinic ligands as multifunc ...... of neuropsychiatric disorders

@ast

Nicotinic ligands as multifunc ...... of neuropsychiatric disorders

@en

prefLabel

Nicotinic ligands as multifunc ...... of neuropsychiatric disorders

@ast

Nicotinic ligands as multifunc ...... of neuropsychiatric disorders

@en

P1433

Q30372351-76686EC8-9910-43C6-BE29-C1B9EF7458A3

P1476

Q30372351-ADDE0AB5-33C9-4A8A-95F6-CE7D0F857881

P2093

Q30372351-0D1B33E7-99B8-4313-9BBB-1378F9E2D07A

Q30372351-40467D44-0005-4139-9ECE-89C1A9E483D2

Q30372351-C6B719B1-C689-4342-9E6A-C63BCB2C6E42

P2860

Q30372351-006408CC-C58A-4AAE-A389-2F96F24502EB

Q30372351-007BE6DF-E298-4ED8-9766-6F8A307A7D58

Q30372351-01AE2F63-1066-469B-A34B-25A7F2EAC9DA

Q30372351-027FC473-8262-4F26-A53B-450DBDAAA39B

Q30372351-03BE7725-EFDD-4705-93B6-59020E4EFB10

Q30372351-08A13D83-DDE8-4E8A-A486-53112182BDCD

Q30372351-0B89B932-1428-4BD1-B17B-470138E65A5D

Q30372351-10C15D01-4805-4F5F-BCF1-F2309E7F9F16

Q30372351-117BA35C-5837-4733-B5A0-1AB982CA66CD

Q30372351-12A4A3BC-8CF0-452B-8277-A36B6D180131

P304

Q30372351-173D52F2-531B-4564-9C21-183BEAE40A75

P31

Q30372351-D85981BB-A446-49EA-9F93-2C280A5678A7

P356

Q30372351-A95B8067-835A-4451-A78A-678552267A60

P407

Q30372351-F45019BF-66E8-41BF-9BCF-49CB4EADC6E1

P433

Q30372351-2B8D8FD9-DC7A-4913-8EEC-EE8593B45E54

P478

Q30372351-6D7384FA-C6D8-40E9-BD4B-E0DB70DFF931

P577

Q30372351-AB5756E2-580C-4609-A951-FD3573F4A312

P5875

Q30372351-6A865D9D-43C2-4050-8463-698860563FBD

P698

Q30372351-247E8C2F-334D-430D-AD6D-0658C3A00CF4

P932

Q30372351-D9622A80-D735-4FC3-969C-A73F6EA6FD4D

P356

J.BCP.2015.07.027

P1433

Biochemical Pharmacology

P1476

Nicotinic ligands as multifunc ...... of neuropsychiatric disorders

@en

P2093

Alvin V Terry

http://www.w3.org/2001/XMLSchema#string

Caterina M Hernandez

http://www.w3.org/2001/XMLSchema#string

Patrick M Callahan

http://www.w3.org/2001/XMLSchema#string

P2860

A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia

A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHD

Mammalian nicotinic acetylcholine receptors: from structure to function

A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists.

Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators

Nicotine as therapy

Shifting from the single to the multitarget paradigm in drug discovery

Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach.

A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder

P304

388-398

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BCP.2015.07.027

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280602370

http://www.w3.org/2001/XMLSchema#string

P698

26231940

http://www.w3.org/2001/XMLSchema#string

P932

4752163

http://www.w3.org/2001/XMLSchema#string